 吕镗烽医学博士
主任医师
吕镗烽，医学博士，东部战区总医院呼吸与危重症医学科主任医师，科主任，色情动漫 教授，美国德州理工大学访问学者，色情动漫 、南京医科大学、南方医科大学和南京中医药大学博士研究生导师。 研究方向：肺癌、肺部感染、呼吸危重症。 学术任职：中国医师协会呼吸医师分会第六届委员会常务委员、中国抗癌协会第一届小细胞肺癌专业委员会委员、江苏省医学会呼吸病学分会副主任委员、江苏省抗癌协会第一届老年肿瘤专业委员会副主任委员、江苏省老年医学学会肿瘤分会常务委员、江苏省医师协会呼吸医师分会常委、江苏省研究型医院协会肺结节和肺癌MDT专委会副主任委员、南京市医学会呼吸病学分会副主任委员；《Translational Lung Cancer Research》杂志(SCI收录)副主编；《医学研究与战创伤救治》第一届编委会编委。 科研工作：先后承担国科金面上项目4项；国家重大科技专项子课题1项；省科技厅社会发展项目2项、省自然科学基金面上项目2项；军科委重点项目1项；其他省部级以上项目多项；近五年已以第一作者、通讯作者身份发表SCI论文60余篇；参编多项肺癌领域指南和专家共识；分别以副主编、编委和译者身份出版专著3部。 科研奖励：先后获得江苏省科学技术一等奖1项，江苏医学科技二等奖1项，江苏省医学新技术引进二等奖1项、教育部高等学校优秀研究成果二等奖1项，教育部科学技术进步二等奖1项
近3年发表SCI论文 1.Hao Xu#,Kaikai Shen#,Bei Jiang,Qiuli Xu,Bingbing Li,Zhangmin Ke,Qinpei Cheng,Suhua Zhu,Dong Wang*,Yong Song*,Tangfeng Lv*.VISTA expressed on tumor cells is regulated by m6A and influences immune microenvironment through STAT3/CCL22 in NSCLC.J Transl Med . 2025 Oct 2;23(1):1043. 通讯作者（1/3）2区/7.5 2.Meng Y,# Han H#, Zhu S#, Li C, Li H, Wang Z, Wu R, Wang Y, Zhang Q, Gong Y, Song Y, Lv T*, Liu H*.Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials.Clin Transl Oncol. 2025 Apr;27(4):1516-1528. doi: 10.1007/s12094-024-03712-0. Epub 2024 Sep 12. 通讯作者（2/2）4区/2.5 3.Cui Y#, Wu Q, Hao Y, Wu G, Cheng Q, Song X, Chen L, Hua X, Jiang Y, Cheng D, Zhu S, Liu X, Song Y*, Lv T*, Zhan P*.Intrapleural anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer with malignant pleural effusion: a prospective, single-arm, single-center, phase I trial.Clin Transl Oncol. 2025 Oct 28. doi: 10.1007/s12094-025-04057-y. Online ahead of print. 通讯作者（2/3）4区/2.5 4.Li L#, Ma L#, Qian H#, Wang Z, Chen M, Wang C, Gu W*, Lv T*, Jin J*.GGPPS Negatively Regulates the Formation of Neutrophil Extracellular Traps in Lipopolysaccharide-Induced Acute Lung Injury.Inflammation. 2025 Jun;48(3):1143-1158.通讯作者（2/3）2区/5 5.Qinpei Cheng #，Xueying Zuo #， Zimu Wang , Wanjun Lu, Yuxin Jiang ， Jiaxin Liu , Xinying Li , Qiuli Xu , Suhua Zhu, Xin Liu , Yong Song* , Ping Zhan* , Tangfeng Lv *.Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion. Respir Res 2025 May 10;26(1):180. 通讯作者（1/3）3区/4.7 6.Yu Li , Shuo Liang , Yanjun Du , Jun Yao , Yuxin Jiang , Wanjun Lu , Qiuxia Wu , Fumihiro Yamaguchi , Marko Jakopović , Wolfgang M Brueckl , Dong Wang , Fang Zhang , Qin Wang* , Tangfeng Lv* , Ping Zhan*Analysis of baseline interstitial lung abnormality on the risk of checkpoint inhibitor-related pneumonitis and survival in advanced non-small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors. Transl Lung Cancer Res 2025 Mar 31;14(3):912-930.通讯作者（3/4）2区/5.5 7.Jing Cheng # ,Wenwen Kang# ,Yueying Chen# ,Luyun Pan ,Hedong Han*,Tangfeng Lv*.Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer.Cancer Immunol Immunother.2025 Feb 25;74(4):124. 通讯作者（1/2）3区/4.6 2025 Feb 19;23(1):99. 通讯作者（2/2）1区/8.2 9.Xin Hua # , Xiaodi Wu #, Liting Lv # , Yanli Gu , Suhua Zhu , Xin Liu , Tangfeng Lv *, Yong Song *.Anlotinib enhances the anti-tumor activity of osimertinib in patients with non-small cell lung cancer by reversing drug resistance. Transl Lung Cancer Res. 2025 Jan 20;14(1):40–57. 通讯作者（2/2）3区/4 10.Lu Chen , Jie Yin , Ke Xu , YuTing Cui , SuHua Zhu , Tian Li* , Tangfeng Lv *, Yong Song* , Ping Zhan*.Novel bioengineered drugs with immunotherapies for malignant pleural effusion: Remodulate tumor immune microenvironment and activate immune system. Crit Rev Oncol Hematol2025 Apr 5:211:104717.通讯作者（2/3）3区/4 11.Hao Y#, Wang Q, Wang K, Chen C, Xu C, Wang D, Song Y, Song Z, Lv T*. Combination regimens as potential treatment of non-small-cell lung cancer patients with HER2 mutation in the real world: a multicenter study.Ther Adv MedOncol.2025May30;17:17588359251338397. eCollection 2025.通讯作者（1/1）2区/4.2 12.Zhang Q#, Wang G, Yan W, Wang D, Yin J, Song Y*, Ye M*, Lv T*.Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLC.Cancer Immunol Immunother. 2025 May 22;74(7):213.通讯作者（1/3）3区/5.1 13.Jin J#, Ma L#, Li L#, Zhou X, Zhu S, Shen K, Xu Q, Jiang B, Gu Y, Ding Q, Qian H*, Lv T*, Song Y*.Geranylgeranyl diphosphate synthase deficiency impairs efferocytosis and resolution of acute lung injury.Respir Res. 2025 May 17;26(1):189. 通讯作者（2/3）3区/5 14.Ma Y#, Chen X, Liang Y, Wang S, Yao Y*, Lv T*, Yuan D*.The granulomatous pulmonary nodules induced by tislelizumab in advanced squamous NSCLC: a case report with challenging differential diagnosis.Transl Lung Cancer Res. 2025 Oct 31;14(10):4675-4681. doi: 10.21037/tlcr-2025-598. Epub 2025 Oct 29. 通讯作者（2/3）3区/3.5 15.ShenM#,ChenY#,ChenJ,YinJ,XuC,WangD*,LvT*. Immune-oncology-microbiome axis in lung cancer: from carcinogenesis to therapy-a narrative review.Transl Lung Cancer Res. 2025 Oct 31;14(10):4638-4657. doi: 10.21037/tlcr-2025-737. Epub 2025 Oct 29.通讯作者（1/2）3区/3.5 16.Chen Y#, Du Y#, Ni J#, Wang D, Zhan P, Song Y, Han H*, Lv T*.Antibody-drug conjugates outperform chemotherapy in EGFR-TKI-resistant NSCLC: a Bayesian network meta-analysis.Ther Adv Med Oncol. 2025 Dec 16;17:17588359251405044. doi: 10.1177/17588359251405044. eCollection 2025.通讯作者（1/2）2区/4.2 17.Jiaxin Liu#,Lingyun Wei#,Qing Miao#,Sutong Zhan,Peilin Chen,Wei Liu,Liang Cao,Dong Wang,Hongbing Liu,Jie Yin,Yong Song,Mingxiang Ye*,Tangfeng Lv* . MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC. J Exp Clin Cancer Res,2024 Nov 15;43(1):302. 通讯作者（1/2） 1区/11.4 19.Liting Lv#,Qing Miao#,Sutong Zhan,Peilin Chen,Wei Liu,Jiawen Lv,Wenjie Yan,Dong Wang,Hongbing Liu,Jie Yin,Jian Feng,Yong Song,Mingxiang Ye*,Tangfeng Lv*.LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer. J Immunother Cancer,2024 Dec 18;12(12):e009444. doi: 10.1136/jitc-2024-009444通讯作者（1/2） 1区/10.3 20.Jiawen Lv#,Jiayan Chen,Yueyue Song,Yanwen Yao,Guannan Wu,Dongmei Yuan,Xiaoling Gu,Xing Li,Chunwei Xu,Baolong Zhou,Mingxiang Ye,Tangfeng Lv*,Dong Wang*,Yong Song* .Co-Delivery of VEGF siRNA and THPP via Metal–Organic Framework Reverses Cisplatin-Resistant Non-Small Cell Lung Cancer and Inhibits Metastasis through a MUC4 Regulating Mechanism. ACS Appl Mater Interfaces,2024 Oct 23;16(42):56910-56925. 通讯作者（3/3） 2区/8.5 21.Yuxin Jiang#,Jingyuan Xie,Qinpei Cheng,Zijing Cai,Ke Xu,Wanjun Lu,Fufeng Wang,Xiaoying Wu,Yong Song*,Tangfeng Lv*,Ping Zhan*. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy. Int Immunopharmacol,2024 Nov 15:141:112901. 通讯作者（2/3） 2区/4.8 22.Yuxin Jiang#,Yueying Chen,Qinpei Cheng,Wanjun Lu,Yu Li,Xueying Zuo,Qiuxia Wu,Xiaoxia Wang,Fang Zhang,Dong Wang,Qin Wang*,Tangfeng Lv*,Yong Song*,Ping Zhan*. A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients.Cancer Immunol Immunother . 2024 Oct 3;73(12):241. 通讯作者（3/4） 2区/4.6 23.Yuxin Jiang#,Tao Liu,Ke Xu,Qinpei Cheng,Wanjun Lu,Jingyuan Xie,Mo Chen,Yu Li,Yanjun Du,Shuo Liang,Yong Song*,Jiang Wu*,Tangfeng Lv*,Ping Zhan*. Lymph nodes rather than pleural metabolic activity in 18F-FDG PET/CT correlates with malignant pleural effusion recurrence in advanced non-small cell lung cancer.Transl Lung Cancer Res . 2024 Sep 30;13(9):2236-2253. 通讯作者（2/4）2区/4 24.Yunchang Meng#,Hedong Han#,Suhua Zhu#,Chuling Li,Huijuan Li,Zhaofeng Wang,Ranpu Wu,Yimin Wang,Qingfeng Zhang,Yanzhuo Gong,Yong Song,Tangfeng Lv*,Hongbing Liu*. Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials. Clin Transl Oncol . 2024 Sep 12. 通讯作者（2/2） 3区/2.8 25.Yu Li#,Yuxin Jiang#,Luyun Pan,Jun Yao,Shuo Liang,Yanjun Du,Dong Wang,Hongbing Liu,Fang Zhang,Qin Wang*,Tangfeng Lv*,Ping Zhan*. First-line chemoimmunotherapy for patients with small-cell lung cancer and interstitial lung abnormality: CIP risk and prognostic analysis.Thorac Cancer . 2024 Dec;15(34):2437-2448. 通讯作者（2/3） 3区/2.3 26.Xiaodi Wu#,Ke Xu#,Ping Zhan,Hongbing Liu,Fang Zhang,Yong Song*,Tangfeng Lv*. Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis. BMC Infect Dis,2024 Feb 21;24(1):234. 通讯作者（1/2） 3区/3.7 27.Xinyu Zhou#,Jiajia Jin,Tangfeng Lv*,Yong Song*. A Narrative Review: The Role of NETs in Acute Respiratory Distress Syndrome/Acute Lung Injury. Int J Mol Sci,2024 Jan 25;25(3):1464. 通讯作者（2/2） 2区/5.6 28.Jingyuan Xie#,Ke Xu,Zijing Cai,Mo Chen,Yuxin Jiang,Jinjun Ye,Xinqing Lin*,Tangfeng Lv*,Ping Zhan*.Efficacy and safety of first-line PDL1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study. Transl Lung Cancer Res. 2024 Mar 29;13(3):526-539. 通讯作者（2/3）2区/4 29.Chen Y#, Han H#, Cheng J#, Cheng Q, Zhu S, Zhan P, Liu H, Song Y*, Lv T*. Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis. Cancer Immunol Immunother. 2024 Jun 4;73(8):155. 通讯作者（1/2） 2区/5.8 30.Xueying Zuo#,Qinpei Cheng#,Zimu Wang,Jiaxin Liu,Wanjun Lu,Guannan Wu,Suhua Zhu,Xin Liu,Tangfeng Lv*,Yong Song*.A novel oral TLR7 agonist orchestrates immune response and synergizes with PD–L1 blockade via type I IFN pathway in lung cancer. Int Immunopharmacol,2024 Aug 20:137:112478. 通讯作者（2/2） 2区/5.6 31.Lu Chen#,Jingyuan Xie,Meiying Zhu,Dong Wang,Hongbin Liu,Ping Zhan,Jie Yin,Mingxiang Ye*,Yong Song*,Tangfeng Lv*.The safety and efficacy of anti-PD-1 inhibitor-based combinational therapy in non-small cell lung cancer patients with oncogenic alterations. Transl Cancer Res,2024 Jan 31;13(1):137-149. 通讯作者（1/3） 3区/4 32.Xiaodi Wu#,Xin Hua#,Ke Xu,Yong Song*,Tangfeng Lv*. Zebrafish in Lung Cancer Research.Cancers (Basel),2023 Sep 26;15(19):4721. 通讯作者（1/2） 2区/5.2 33.Aying Wang#,Tangfeng Lv*,Yong Song*.Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer. Cell Immunol,2023 Aug 29;391-392:104760. 通讯作者(1/2)2区/5.2 34.Mo Chen#,Lingyun Wei#,Qin Wang#,Jingyuan Xie,Ke Xu,Tangfeng Lv*,Yong Song*,Ping Zhan*.Efficacy of different therapies for brain metastases of non-small cell lung cancer: a systematic review and meta-analysis.Transl Lung Cancer Res. 2023 Apr 28;12(4):689-706.通讯作者（3/3） 2区/4 35.Ke Xu#,Xiaodi Wu,Lu Chen,Jingyuan Xie,Xin Hua,Mo Chen,Yuxin Jiang,Hongbing Liu,Fang Zhang,Tangfeng Lv*,Yong Song*,Ping Zhan*.Risk factors for symptomatic malignant pleural effusion recurrence in patients with actionable mutations in advanced lung adenocarcinoma. Transl Lung Cancer Res,2023 Sep 28;12(9):1887-1895.通讯作者（3/3） 2区/4 36.Zijing Cai#, Xiaoling Gu#, Jingyuan Xie#, Di Cheng, Jiayan Chen, Jing Cheng, Jinjun Ye*, Tangfeng Lv*.Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: a multicenter retrospective analysis. Transl Lung Cancer Res 2023;12(10):1987-2000.通讯作者（1/2） 2区/4 37.Xin Hua#,Xiaodi Wu#,Ke Xu,Ping Zhan,Hongbing Liu,Fang Zhang,Tangfeng Lv*,Yong Song*. Zebrafish patient-derived xenografts accurately and quickly reproduce treatment outcomes in non-small cell lung cancer patients. Exp Biol Med (Maywood). 2023 Feb;248(4):361-369. 通讯作者（2/2）3区/3.2 1 .项目负责人：吕镗烽；项目名称：SPARC⁺ CAF通过整合素-FAK-YAP/TAZ轴调控CD8⁺ T细胞耗竭在恶性胸腔积液免疫微环境中的作用和机制研究；项目类别：国家自然科学基金--面上项目；项目批准号：82570135；研究时限：2026.01-2029.12；项目经费：49.00万元。 2. 项目负责人：吕镗烽；项目名称：中度到重度慢性阻塞性肺疾病患者规范化呼吸康复真实世界研究；项目类别：国家卫生健康委医药卫生科技发展中心项目；研究时限：2025.07-2027.06；项目经费：20.00万元 3. 项目负责人：吕镗烽；项目名称：《胸膜疾病精准诊疗方案研究》子课题六“胸膜疾病精准分型和治疗新方案建立及多中心研究”； 项目类别：癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项子课题; 项目批准号：SQ2024AAA030091; 研究时限：2024.12-2028.11；项目经费：30.00万元 4 项目负责人：吕镗烽；项目名称：磷酸化MET作为新型生物标记物预测MET抑制剂在非小细胞肺癌患者中敏感性的临床研究；项目类别：希思科—领航MET异常实体瘤研究（增补）基金项目; CY-2023AZMETMS-0028; 研究时限：2024.07-2027.06;项目经费：15.00万元（横向课题） 5. 项目负责人：吕镗烽；项目名称：Mdm2调控FBW7蛋白稳定性诱导奥希替尼耐药的机制研究；项目类别：江苏省自然科学基金面上项目；项目批准号：BK20242092；研究时限：2024.09-2027.08；项目经费：15.00万元。 6．项目负责人：吕镗烽；项目名称：C1Q+巨噬细胞亚群通过STING-IFN-γ-HK2信号通路调控恶性胸腔积液免疫微环境的机制研究；项目类别：国家自然科学基金--面上项目；项目批准号：82370096；研究时限：2024.01-2027.12；项目经费：48.00万元。 7. 项目负责人：吕镗烽；项目名称：基于******异常状态******研究；项目类别：***项目（涉密）；研究时限：2023.07-2025.06，项目经费：300.00万元。 8. 项目负责人：吕镗烽；项目名称：NK510联合PD-1单抗治疗复发难治晚期NSCLC的疗效和安全性及生物标志物探索：一项前瞻性、多中心、单臂临床研究；项目类别：东部战区总医院-领航专项；项目批准号：22LCYY-LH3；研究时限：2023.01-2025.12；项目经费：40.00万元。 9.项目负责人：吕镗烽；项目名称：METTL3介导ULBP2 mRNA m6A甲基化修饰调控非小细胞肺癌Anti-PD1/PD-L1治疗获得性耐受的机制研究；项目类别：国家自然科学基金--面上项目；项目批准号：82172728；研究时限：2022.01-2025.12；项目经费：55.00万元。 1、2023年12月江苏医学科技二等奖：基于液体活检指导下的肺癌精准诊治和临床转项化研究，排名第1； 2、2022年2月江苏省科技进步一等奖：肺癌诊治创新平台的建立推广及临床转化；排名第2； 3、2020年11月江苏省医学新技术引进二等奖：长非编码RNA在非小细胞癌早期诊断、预后和发病机制中的研究，排名第1； 4、2021年3月高等学校优秀研究成果二等奖：突发事件应急医疗救援模式创新和应用研究，排名第4；5、2017年2月教育部科学技术进步二等奖：非小细胞肺癌精准诊治转化研究及临床应用，排名第2； |